Clinical trial
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With…
NCT00118963 · Steno Diabetes Center Copenhagen, Other · Completed
Key facts
| NCT number | NCT00118963 |
|---|---|
| Title | Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes |
| Official title | Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control With Oral Hypoglycaemic Agents |
| Lead sponsor | Steno Diabetes Center Copenhagen, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Metformin, Insulin BIAsp30 (Novolog 70/30), Repaglinide, Placebo-Metformin, Placebo-Repaglinide |
| Enrollment | 102 |
| Start date | Jan 1, 2003 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Jul 12, 2005 |
| Last update posted | Dec 8, 2008 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: